Madrigal, China's Suzhou Ribo sign license deal for liver‑disease programs

Feb 11 (Reuters) - Madrigal Pharmaceuticals said on Wednesday it has entered into a global licensing deal with China-based Suzhou Ribo Life Science for six preclinical small interfering RNA programs ...

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing ...
Stocktwits on MSN

Madrigal doubles down on MASH with a $4.4 billion licensing deal with China’s Ribo

Madrigal Pharmaceuticals (MDGL), on Wednesday, announced an exclusive global licensing agreement with Suzhou Ribo Life ...
The Pharma Letter

Madrigal expands its MASH pipeline via Ribo deal

US biopharma Madrigal Pharmaceuticals, which is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced an exclusive global license ...
Pharmabiz

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...

Madrigal, Suzhou Ribo in license deal for liver‑disease programs

Feb 11 () - Madrigal Pharmaceuticals ‌said ‌on Wednesday it ​has signed an exclusive global ‌license ⁠agreement with China-based ⁠Suzhou Ribo Life ​Science and ​its ​subsidiary Ribocure ...